214 related articles for article (PubMed ID: 31678207)
1. A review of recently described genetic alterations in central nervous system tumors.
Lucas CG; Solomon DA; Perry A
Hum Pathol; 2020 Feb; 96():56-66. PubMed ID: 31678207
[TBL] [Abstract][Full Text] [Related]
2. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
Ballester LY; Huse JT; Tang G; Fuller GN
Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.
DeWitt JC; Jordan JT; Frosch MP; Samore WR; Iafrate AJ; Louis DN; Lennerz JK
Neuro Oncol; 2017 Nov; 19(12):1640-1650. PubMed ID: 29016871
[TBL] [Abstract][Full Text] [Related]
4. Practice-Changing Abstracts From the 2016 Society for Neuro-Oncology Annual Scientific Meeting.
Penas-Prado M
Am Soc Clin Oncol Educ Book; 2017; 37():187-191. PubMed ID: 28561706
[TBL] [Abstract][Full Text] [Related]
5. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.
Gierke M; Sperveslage J; Schwab D; Beschorner R; Ebinger M; Schuhmann MU; Schittenhelm J
J Cancer Res Clin Oncol; 2016 Jan; 142(1):89-100. PubMed ID: 26115961
[TBL] [Abstract][Full Text] [Related]
6. The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.
Komori T
Neurol Med Chir (Tokyo); 2017 Jul; 57(7):301-311. PubMed ID: 28592714
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system.
Gritsch S; Batchelor TT; Gonzalez Castro LN
Cancer; 2022 Jan; 128(1):47-58. PubMed ID: 34633681
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.
Gupta R; Webb-Myers R; Flanagan S; Buckland ME
J Clin Pathol; 2011 Oct; 64(10):835-44. PubMed ID: 21752797
[TBL] [Abstract][Full Text] [Related]
9. The molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous system.
Komori T
Brain Tumor Pathol; 2021 Jan; 38(1):1-3. PubMed ID: 33398472
[No Abstract] [Full Text] [Related]
10. Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities.
Wood MD; Halfpenny AM; Moore SR
Diagn Pathol; 2019 Apr; 14(1):29. PubMed ID: 30967140
[TBL] [Abstract][Full Text] [Related]
11. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
Louis DN; Perry A; Reifenberger G; von Deimling A; Figarella-Branger D; Cavenee WK; Ohgaki H; Wiestler OD; Kleihues P; Ellison DW
Acta Neuropathol; 2016 Jun; 131(6):803-20. PubMed ID: 27157931
[TBL] [Abstract][Full Text] [Related]
12. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
[TBL] [Abstract][Full Text] [Related]
13. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update.
Whitfield BT; Huse JT
Brain Pathol; 2022 Jul; 32(4):e13062. PubMed ID: 35289001
[TBL] [Abstract][Full Text] [Related]
14. World Health Organization 2016 Classification of Central Nervous System Tumors.
Diamandis P; Aldape K
Neurol Clin; 2018 Aug; 36(3):439-447. PubMed ID: 30072064
[TBL] [Abstract][Full Text] [Related]
15. New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy.
Fuller CE; Jones DTW; Kieran MW
Am Soc Clin Oncol Educ Book; 2017; 37():753-763. PubMed ID: 28561665
[TBL] [Abstract][Full Text] [Related]
16. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
17. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
Weller M; Reifenberger G
Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376
[TBL] [Abstract][Full Text] [Related]
18. IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker.
Kurian KM; Haynes HR; Crosby C; Hopkins K; Williams M
Br J Neurosurg; 2013 Aug; 27(4):442-5. PubMed ID: 23451940
[TBL] [Abstract][Full Text] [Related]
19. [The role of the pathologist in the diagnosis and therapy planning of central nervous system tumors. Prognostic and predictive markers].
Turányi E; Hanzély Z; Bálint K; Reiniger L
Magy Onkol; 2013 Dec; 57(4):215-21. PubMed ID: 24353986
[TBL] [Abstract][Full Text] [Related]
20. Embryonal Tumors of the Central Nervous System: The WHO 2016 Classification and New Insights.
Pinheiro JAF; de Almeida JCM; Lopes JMPB
J Pediatr Hematol Oncol; 2021 Apr; 43(3):79-89. PubMed ID: 32925406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
